Search This Blog

Monday, November 2, 2020

Germany requests 5% of EU supply of Gilead remdesivir

Germany has requested around 5% of the supply of remdesivir under a six-month European Union supply deal, its health ministry said on Monday, despite criticism of the deal due to a lack of evidence about the antiviral drug's effectiveness in treating COVID-19.

Berlin has requested 155,000 vials of remdesivir under the EU's six-month deal to buy up to 3 million vials from U.S. drug maker Gilead, the ministry said in a statement.

A course of treatment for COVID-19 requires six doses and costs 2,070 euros ($2,407) per treatment, under the terms of the deal.

Medical experts have called on Brussels to renegotiate the 1 billion euro contract signed with Gilead last month after remdesivir showed poor results in a large trial conducted by the World Health Organization.

https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Gilead-Sciences-Germany-requests-5-of-EU-supply-of-remdesivir-31674521/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.